ALA

Arovella Therapeutics confirms anti-tumour effect of lead drug ALA-101 in treating certain cancers

Arovella Therapeutics (ASX: ALA) has presented new data at the American Association for Cancer Research annual meeting relating to lead drug ALA-101 as a novel ‘off-the-shelf’ therapy to treat CD19-expressing leukemias and lymphomas. The data presented used iNKT (invariant natural killer) cells expressing a chimeric antigen receptor (CAR) which targets the CD19 biomarker. The cells […]